entertainment -WSS

entertainment

author：knowledge 2025-10-01 15:29:55 - browse：9123

Illustration of sound waves coming out of an ear and at the end of these waves we have a figure trying to push back against them and contain them. -- health coverage from STAT — Advances in gene therapy could eventually "cure" many forms of congenital deafness. The changes have many deaf people worried about the future of their communities. Eros Devishi for STAT

When Yilai Shu was training to be an otolaryngologist in Shanghai, in the mid 2000s, he often met parents with congenitally deaf kids.

“They always asked me, ‘Do you have any drugs to treat our kids?’ said Shu, who is hearing and a professor at Fudan University in China. “That’s what really inspired me to think about developing a drug.”

Decades later, Shu is closer than ever to such a drug. In October, he presented extraordinary data at a conference: His team had successfully enabled hearing in four congenitally deaf children using gene therapy. The work is the culmination of decades of genetic research and has spurred companies like Regeneron and Eli Lilly to swoop in and back other groups developing similar treatments.

The hearing gains are modest and the technology is currently limited to a type of deafness that only affects 1% to 8% of deaf people globally, but some experts suggest that gene therapy could eventually apply to as many as half of all congenitally deaf people. These treatments would have massive implications for the 12,000 kids born with hearing loss in the United States every year.

“This has been the dream of our field for 30-plus years to come up with a molecular treatment to give people real, natural hearing, that they were originally intended to have,” said Larry Lustig, a hearing otolaryngologist at Columbia University who is leading a Regeneron-backed trial showing promising results using gene therapy to treat deafness. “This is going to be transformative.”

But this transformative technology faces a problem: not all deaf people want it.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Addiction experts warn against a second 'war on drugs'

hotspot

leisure time

WSS

With measles on the rise, a personal story of a devastating disease

Why scientists need input from humanists on sensitive research

FDA advisers back CAR

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Change Healthcare outage fallout shows need for new oversight

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

leisure time

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Bright Health sells Medicare Advantage business to Molina

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

After affirmative action ruling, medical educators look to 'holistic review'

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Supreme Court strikes down use of affirmative action

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Malaria cases in Florida and Texas: Here’s what you need to know

Helping hospitals and community health centers plan for resilience

After affirmative action ruling, medical educators look to 'holistic review'

Boston's new lab space is opening empty

Wikipedia

EPA limits use of carcinogenic gas for sterilizing medical devices

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Data integrity in scientific journals requires "effort" by publishers, institutions

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Big Tobacco's 'harm reduction': Is it for real, or a sham?

NVIDIA and Google execs on the future of AI and drug discovery

leisure time

hotspot

leisure time

hotspot